Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of CBT exposure therapy for body dysmorphic disorder
NL-OMON33898Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in body dysmorphic disorder (BDD), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in BDD-YBOCS and Time of onset of change on BDD-YBOCS. Planned start Apr 2009; status: not yet recruiting.
02
Drugs
d-cycloserine
03
Conditions
body dysmorphic disorder (BDD)
Beyond the preview
Go deeper on NL-OMON33898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33898.